Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 420

1.

After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.

Sacks FM.

Am J Cardiol. 2008 Dec 22;102(12A):34L-40L. doi: 10.1016/j.amjcard.2008.09.073.

PMID:
19084088
[PubMed - indexed for MEDLINE]
2.

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M; FIELD study investigators.

Lancet. 2005 Nov 26;366(9500):1849-61. Erratum in: Lancet. 2006 Oct 21;368(9545):1415. Lancet. 2006 Oct 21;368(9545):1420.

PMID:
16310551
[PubMed - indexed for MEDLINE]
3.

The role of fenofibrate in clinical practice.

Zambon A, Cusi K.

Diab Vasc Dis Res. 2007 Sep;4 Suppl 3:S15-20.

PMID:
17935056
[PubMed - indexed for MEDLINE]
Free Article
4.

More clinical lessons from the FIELD study.

Fazio S.

Cardiovasc Drugs Ther. 2009 Jun;23(3):235-41. doi: 10.1007/s10557-008-6160-5. Review.

PMID:
19160032
[PubMed - indexed for MEDLINE]
5.

Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.

Steiner G.

Am J Cardiol. 2008 Dec 22;102(12A):28L-33L. doi: 10.1016/j.amjcard.2008.09.072. Review.

PMID:
19084087
[PubMed - indexed for MEDLINE]
6.

Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

Rajamani K, Colman PG, Li LP, Best JD, Voysey M, D'Emden MC, Laakso M, Baker JR, Keech AC; FIELD study investigators.

Lancet. 2009 May 23;373(9677):1780-8. doi: 10.1016/S0140-6736(09)60698-X.

PMID:
19465233
[PubMed - indexed for MEDLINE]
Free PMC Article
7.

How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.

Steiner G.

Cardiovasc Drugs Ther. 2009 Oct;23(5):403-8. doi: 10.1007/s10557-009-6190-7. Review.

PMID:
19757004
[PubMed - indexed for MEDLINE]
8.

Fibrates after the FIELD study: Some answers, more questions.

Wierzbicki AS.

Diab Vasc Dis Res. 2006 Dec;3(3):166-71. Review.

PMID:
17160911
[PubMed - indexed for MEDLINE]
Free Article
9.

Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

Keating GM, Croom KF.

Drugs. 2007;67(1):121-53. Review.

PMID:
17209672
[PubMed - indexed for MEDLINE]
10.

"If it ain't broke, don't fix it": a commentary on the positive-negative results of the ACCORD Lipid study.

Tenenbaum A, Fisman EZ.

Cardiovasc Diabetol. 2010 Jun 15;9:24. doi: 10.1186/1475-2840-9-24.

PMID:
20550659
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.

Vergès B.

Curr Opin Lipidol. 2006 Dec;17(6):653-8. Review.

PMID:
17095910
[PubMed - indexed for MEDLINE]
12.

[Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].

Radermecker RP, Scheen AJ.

Rev Med Liege. 2005 Dec;60(12):957-61. French.

PMID:
16457397
[PubMed - indexed for MEDLINE]
13.

Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

Keech AC, Mitchell P, Summanen PA, O'Day J, Davis TM, Moffitt MS, Taskinen MR, Simes RJ, Tse D, Williamson E, Merrifield A, Laatikainen LT, d'Emden MC, Crimet DC, O'Connell RL, Colman PG; FIELD study investigators.

Lancet. 2007 Nov 17;370(9600):1687-97. Epub 2007 Nov 7.

PMID:
17988728
[PubMed - indexed for MEDLINE]
14.

Fibrates and microvascular complications in diabetes--insight from the FIELD study.

Ansquer JC, Foucher C, Aubonnet P, Le Malicot K.

Curr Pharm Des. 2009;15(5):537-52. Review.

PMID:
19199980
[PubMed - indexed for MEDLINE]
15.
16.

FIELDS of dreams, fields of tears: a perspective on the fibrate trials.

Wierzbicki AS.

Int J Clin Pract. 2006 Apr;60(4):442-9. Review.

PMID:
16620358
[PubMed - indexed for MEDLINE]
17.

Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.

Jones PH.

Am J Cardiol. 2008 Dec 22;102(12A):41L-47L. doi: 10.1016/j.amjcard.2008.09.074. Review.

PMID:
19084089
[PubMed - indexed for MEDLINE]
18.

Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

ACCORD Study Group, Buse JB, Bigger JT, Byington RP, Cooper LS, Cushman WC, Friedewald WT, Genuth S, Gerstein HC, Ginsberg HN, Goff DC Jr, Grimm RH Jr, Margolis KL, Probstfield JL, Simons-Morton DG, Sullivan MD.

Am J Cardiol. 2007 Jun 18;99(12A):21i-33i. Epub 2007 Apr 16.

PMID:
17599422
[PubMed - indexed for MEDLINE]
19.

Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

Fazio S.

Clin Ther. 2008 Feb;30(2):294-306. doi: 10.1016/j.clinthera.2008.02.004. Review.

PMID:
18343268
[PubMed - indexed for MEDLINE]
20.

Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.

Hamilton SJ, Chew GT, Davis TM, Watts GF.

Clin Sci (Lond). 2010 Feb 23;118(10):607-15. doi: 10.1042/CS20090568.

PMID:
20047560
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk